1430720-28-7

Basic information

• Product Name: 4-(1-ethyl-1H-pyrazol-5-yl)benzene-1,2-diamine
• CAS NO: 1430720-28-7
• Molecular Weight: 202.259
• Mol File: 1430720-28-7.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 4-(1-ethyl-1H-pyrazol-5-yl)benzene-1,2-diamine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(1-ethyl-1H-pyrazol-5-yl)benzene-1,2-diamine(1430720-28-7)
• EPA Substance Registry System: 4-(1-ethyl-1H-pyrazol-5-yl)benzene-1,2-diamine(1430720-28-7)

Safety Data

• Hazardous Substances Data: 1430720-28-7(Hazardous Substances Data)

Upstream product

• 1095080-54-8 (1-ethyl-1H-pyrazol- 5-yl)boronic acid 
• 1575-37-7 4-Bromo-benzene-1,2-diamine 

Relevant articles and documents

Discovery of new benzothiazole-based inhibitors of breakpoint cluster region-abelson kinase including the T315i mutant

The existence of drug resistance caused by mutations in the break-point cluster region-Abelson tyrosine kinase (Bcr-Abl) kinase domain remains a clinical challenge due to limited effective treatment options for chronic myeloid leukemia (CML). Herein we report a novel series of benzothiazole-based inhibitors that are effective against wild-type and T315I mutant Bcr-Abl kinases. The original hit compound, nocodazole, was extensively modified through a structure-based drug design strategy, especially by varying the groups at the C2 and C6 positions of the scaffold. In addition, the introduction of water-solubilizing groups at the terminal ethyl group resulted in enhanced physicochemical properties and potency in cellular inhibition. Several compounds inhibited the kinase activity of both wild-type Bcr-Abl and the T315I mutant with IC50 values in the picomolar range and exhibited good antiproliferative effects on Ba/F3 cell lines transformed with either wild-type or T315I mutant Bcr-Abl.